Pharma Analytics

In recent years, rare disease products, or orphan drugs, have observed an increase in research and development (R&D) focus from pharma, biopharma, and biotech companies. A study ...

Introduction With the uncertainty in these pandemic times, sales forces are dwindling, and access to a broader selection of physicians, hospitals, and integrated delivery networks (IDNs) is ...

This blog is the second of a two-part series. It highlights three of the six reasons for emerging pharma companies to move away from siloed point-solutions and choose an integrated ...

The COVID-19 pandemic has accelerated several changes in the pharmaceutical commercial model that were already underway: the digitization of sales rep-physician engagement, an influx of ...

The pandemic has brought forth several unexpected changes to companies’ business and commercial models across industries. For the life sciences industry, 2020 pushed organizations to ...

States Feeling Budget Pressures Due to Expanding Medicaid Enrollment Economic recession effects induced by state and local public policy responses to the COVID-19 pandemic (according to the ...

What Should the Pharma Industry Learn from the 2020 Elections? 1.1 Current State of Party Control of the White House and Congress The November 2020 elections for President, Senate, and ...

In addition to Axtria’s presentations and posters (discussed in our first blog on Axtria’s participation in PMSA’s 2018 Annual Conference), Axtria’s Principal, Devesh Verma, Ph.D., will be ...